Slone Partners Recruits Co-CEO for EarlyDiagnostics

January 18, 2024 – Life sciences-focused search firm Slone Partners has placed Gregory C. Critchfield as co-CEO of EarlyDiagnostics (EarlyDx), a leading company in liquid biopsy methylome detection of early cancer. “Greg Critchfield is a highly accomplished and respected life sciences executive with the deep knowledge and experience needed to drive a growth-focused company forward,” said Leslie Loveless, managing partner and CEO at Slone Partners. “He will be a tremendously valuable addition to the EarlyDiagnostics leadership team as the company prepares to launch its new commercial products.”

“We are thrilled to welcome Greg to EarlyDx,” said Jasmine Zhou, co-founder and co-CEO of EarlyDiagnostics, Inc. “He possesses the vision, leadership, and a proven reputation to help transform startups into commercially active growth companies. With this addition to our experienced leadership team, EarlyDx is well-positioned to drive forward into our next phase of growth and success.”

Dr. Critchfield is an experienced business leader with more than 30 years of operational and strategic experience in many diagnostic enterprises. As a board member, former chairman and CEO, he led Sera Prognostics from its very early financing stages in 2010 through and beyond its successful IPO in 2021. During his tenure with Sera Prognostics, he worked to build discovery of multiple proteomic biomarker predictions of important pregnancy outcomes. Dr. Critchfield headed the creation of strategic partnerships with non-profit, commercial, health insurance and other healthcare organizations to generate evidence of clinical validity of Sera’s  PreTRM test, and the clinical utility of applying it in prospective controlled clinical studies to enable more proactive interventions to improve pregnancy outcomes.

Prior his tenure with Sera, Dr. Critchfield served as president of Myriad Genetic Laboratories, where he and his team built Myriad into one of the world’s leading molecular diagnostics companies, by commercializing DNA sequencing genetic tests for inherited cancer predisposition including breast, ovarian, colorectal, and endometrial cancers. Before that, he was chief medical and science officer for Quest Diagnostics, Inc., overseeing medical and innovation activities in its transition from Corning Clinical Laboratories toward the company becoming a publicly traded enterprise. Dr. Critchfield has served on the faculty of three medical schools: University of Minnesota, Wayne State University, and Duke University and as a practicing clinical pathologist with Intermountain Healthcare.

“I am very excited to join Jasmine and the EarlyDx team at this time when the company is on the cusp of launching commercial products this year,” said Dr. Critchfield. “EarlyDx has the world-leading platform for providing early cancer detection services using its innovative combination of proprietary chemistries with advanced bioinformatics. The EarlyDx team and its technology are held in high distinction, evidenced by a large number of high-quality publications in esteemed scientific journals for work in this field. The company’s expanding leadership in liquid biopsy generates great confidence in the enormous potential of EarlyDx’s approach to bring accurate early cancer detection testing to patients that is convenient, affordable, and non-invasive.”

Related: Slone Partners Recruits Chief Business Officer for 1910 Genetics

Headquartered in Los Angeles, EarlyDx is devoted to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine. Its proprietary technologies for cost-effective cell-free DNA methylome sequencing, in combination with its powerful AI algorithms, have achieved high performance results in multi-cancer early detection and localization.

Life Sciences Consultants

Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”

Slone Partners Fills Board Positions for Fusion Pharmaceuticals

Slone Partners has recruited Jeremy Bender, Teresa Bitetti, and David Meek as members of the board of directors at Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. “Jeremy Bender, Teresa Bitetti, and David Meek are all very accomplished and highly respected leaders in the fields of biopharmaceuticals, oncology, and therapeutics,” said Leslie Loveless, CEO of Slone Partners. “They bring extraordinary business and scientific experience and knowledge to the board at a very exciting time in the company’s history.”

In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.

Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.

Related: Slone Partners Recruits CFO for Clear Labs

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Executive Editor; Lily Fauver, Senior Editor – Hunt Scanlon Media

Share This Article


Notify of
Inline Feedbacks
View all comments